Pharvaris Reports Positive Phase 3 Data for HAE Prophylaxis Treatment

Key Facts

In a move reflecting the ongoing progress in the biotech sector's efforts to treat rare diseases, Pharvaris has announced positive topline results from its pivotal CHAPTER-3 Phase 3 study. The trial evaluated deucrictibant XR tablets for the prevention of hereditary angioedema (HAE) attacks. According to reports, the study successfully met its primary endpoint and all secondary efficacy endpoints with statistical significance, marking a critical milestone in the drug's clinical development.

The company plans to submit marketing authorization applications based on this clinical data starting in the first half of 2027. This announcement serves as a major de-risking event for the firm's late-stage pipeline, although the 2027 filing timeline suggests that immediate commercialization is not yet on the horizon. Per market data and company filings, the success of this oral prophylaxis treatment is expected to be a key driver for the company's long-term regulatory strategy.

Monitoring the market response, PHVS stood at $35.25 (close September 4, 2026), having reached a day high of $36.39 during that session. Investors should watch for further updates regarding interactions with regulatory authorities like the FDA, as these will determine the ultimate path to market. With no major healthcare-specific catalysts in the immediate economic calendar, the stock's trajectory will likely depend on the continued analysis of these Phase 3 results.